|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
3 months to Mar 31, 2023
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Cash flows from operating activities: | |||||
| Net loss | |||||
| Adjustments to reconcile net loss to net cash used in operating activities: | |||||
| Loss on disposal of fixed assets | |||||
| Depreciation and amortization | |||||
| Stock-based compensation | |||||
| Restricted stock awards granted | |||||
| Changes in lease liabilities | |||||
| Non-cash interest expense on CIRM liability | |||||
| Changes in operating assets and liabilities: | |||||
| Receivables | |||||
| Prepaid expenses and other assets | |||||
| Other assets | |||||
| Accounts payable and accrued expenses | |||||
| Accounts payable and accrued expenses, related party | |||||
| Deferred revenue | |||||
| Net cash used in operating activities | |||||
| Cash flows from investing activities: | |||||
| Purchase of marketable securities | |||||
| Proceeds from sales and maturities of marketable securities | |||||
| Purchases of property and equipment | |||||
| Payments for leasehold improvements | |||||
| Payments for construction in progress | |||||
| Net cash provided by (used in) investing activities | |||||
| Cash flows from financing activities: | |||||
| Net proceeds from sale of common stock | |||||
| Proceeds from exercise of stock awards and warrants | |||||
| Net cash provided by financing activities | |||||
| Net increase (decrease) in cash and cash equivalents | |||||
| Cash and cash equivalents balance at beginning of period | |||||
| Cash and cash equivalents balance at end of period | |||||
| Supplemental disclosures of cash flow information: | |||||
| Interest paid in cash | |||||
| Income taxes paid in cash | |||||
| Initial recognition of right-of-use asset | |||||
Loading...